On April 8, 2024, Helix BioPharma Corp. closed the transaction. The Offering is subject to final approval of the Toronto Stock Exchange.

The common shares are subject to a hold period of four months and one day expiring on August 9, 2024 in accordance with applicable securities laws. In connection with the closing. The company paid a cash fee of 10% of gross proceeds equal to CAD 191,500.005 raised to an eligible finder.